COMPANY
Puma Biotechnology
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Clinical Research Associate - Remote Position | Clinical Operations | Not stated | Oct 12, 2026 |
| Senior Oncology Sales Specialist - Austin, TX | Sales | Not stated | Oct 12, 2026 |
| Senior Oncology Sales Specialist - Boston, MA | Sales | Not stated | Oct 12, 2026 |
| Senior Oncology Sales Specialist - Long Island | Sales | Not stated | Oct 12, 2026 |
| Senior Oncology Sales Specialist - Detroit, MI | Sales | Not stated | Oct 12, 2026 |
Trial and FDA signals
- New trial + clinical hiring Started a Phase 2 trial (NCT07465757, actual start Sep 17, 2026); 1 clinical-operations role open. ClinicalTrials.gov NCT07465757 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · ClinicalTrials.gov NCT07465757
leadSponsor.name='Puma Biotechnology, Inc.'; phases=['PHASE2']; overallStatus=RECRUITING; startDateStruct={date:2026-09-17,type:ACTUAL}; studyFirstPostDate=2026-03-12; briefTitle='A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)'
- Sep 17, 2026 · ClinicalTrials.gov NCT07465757
Timeline
- Trial start Phase 2: A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) source ↗
- Trial start Phase 2: A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer source ↗
- Trial start Phase 2: A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer source ↗
- Trial start Phase 2: A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib source ↗
- Trial start —: HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib source ↗
- Trial start Phase 2: An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide source ↗
- Trial start Phase 1: Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects source ↗
- Trial start Phase 2: Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations source ↗
- Trial start Phase 2: Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer source ↗
- Trial start Phase 3: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Met source ↗
- Trial start Phase 1: Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib source ↗
- Trial start —: A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects source ↗
- Trial start Phase 1: A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor source ↗
- Trial start Phase 1/Phase 2: Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer source ↗
- Trial start Phase 2: Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer source ↗
- Trial start Phase 3: Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer source ↗
- Trial start Phase 1: Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors source ↗
- Trial start Phase 1: Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors source ↗
- Trial start Phase 1: Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib source ↗
- Trial start Phase 1: Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin source ↗
- Trial start Phase 1: Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease source ↗
- Trial start Phase 2: Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer source ↗
- Trial start Phase 1: Study Evaluating TwoTablet Formulations of Neratinib (HKI-272) source ↗
- Trial start Phase 1/Phase 2: Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer source ↗
- Trial start Phase 1: Study Evaluating Safety And Tolerability, Solid Tumor source ↗
Upcoming milestones
- Oct 30, 2027 (ESTIMATED) · Phase 2 · A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer · NCT06095505
- Dec 30, 2027 (ESTIMATED) · Phase 2 · A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer · NCT06369285
- Mar 31, 2028 (ESTIMATED) · Phase 2 · A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · NCT07465757
Clinical trials (lead sponsor) 38
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06369285 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Recruiting | Nov 19, 2024 | Dec 30, 2027 (estimated) |
| NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) | Phase 2 | Recruiting | Sep 17, 2026 | Mar 31, 2028 (estimated) |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Feb 8, 2024 | Oct 30, 2027 (estimated) |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | Phase 2 | Terminated | Sep 30, 2013 | Jan 2, 2023 (actual) |
| NCT04366713 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | Phase 2 | Completed | Jun 30, 2020 | Dec 28, 2021 (actual) |
| NCT02400476 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide | Phase 2 | Completed | 2015-02 | Apr 22, 2021 (actual) |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | Phase 3 | Completed | Mar 29, 2013 | Sep 28, 2018 (actual) |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer | Phase 3 | Completed | Jul 9, 2009 | Aug 21, 2014 (actual) |
| NCT03786107 | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib | Not listed | Terminated | Mar 14, 2019 | Jan 21, 2021 (actual) |
| NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | Phase 1 | Completed | 2010-04 | 2011-03 (actual) |
| NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | Phase 1 | Completed | 2008-10 | 2011-01 (actual) |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | Phase 1/Phase 2 | Completed | 2010-04 | 2016-07 (actual) |
| NCT00838539 | Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors | Phase 1 | Completed | 2009-04 | 2011-06 (actual) |
| NCT00146172 | Study Evaluating HKI-272 in Tumors | Phase 1 | Completed | 2003-11 | 2007-01 (actual) |
| NCT00397046 | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | Phase 1 | Completed | 2006-11 | 2009-03 (actual) |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | Phase 1/Phase 2 | Completed | Dec 9, 2008 | 2010-11 (actual) |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer | Phase 2 | Completed | Aug 21, 2009 | 2013-08 (actual) |
| NCT00300781 | Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | Phase 2 | Completed | Aug 4, 2006 | 2008-04 (actual) |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | Phase 2 | Completed | Feb 4, 2009 | 2011-03 (actual) |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | Phase 1/Phase 2 | Completed | Apr 29, 2008 | 2009-10 (actual) |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | 1 | Completed | Sep 11, 2007 | 2011-05 (actual) |
| NCT00398567 | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer | 1 | Completed | Apr 4, 2007 | Jul 31, 2009 (actual) |
| NCT01827267 | Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | Phase 2 | Completed | Jul 1, 2013 | Sep 20, 2016 (actual) |
| NCT00958724 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors | Phase 1 | Completed | 2009-07 | 2010-04 (actual) |
| NCT00266877 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | Phase 2 | Completed | 2005-12 | 2009-01 (actual) |
| NCT00366600 | Study Evaluating HKI-272 Administered to Healthy Subjects | Phase 1 | Completed | 2006-07 | 2006-12 (actual) |
| NCT02334501 | Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects | Phase 1 | Completed | 2014-08 | 2014-10 (actual) |
| NCT00864487 | Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib | Phase 1 | Completed | 2009-04 | 2009-05 (actual) |
| NCT00380328 | HKI-272 Ketoconazole Drug Interaction Study | Phase 1 | Completed | 2006-10 | Not listed |
| NCT00860223 | Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin | Phase 1 | Completed | 2009-04 | 2009-04 (actual) |
| NCT00550212 | Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects | Phase 1 | Completed | 2008-03 | 2008-04 (actual) |
| NCT00932464 | Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib | Phase 1 | Withdrawn | 2012-08 | 2012-08 (estimated) |
| NCT00814060 | Study Evaluating TwoTablet Formulations of Neratinib (HKI-272) | Phase 1 | Completed | 2009-01 | 2009-03 (actual) |
| NCT00757809 | Study Evaluating The Tolerability Of Multiple Doses Of HKI-272 | Phase 1 | Completed | 2008-10 | 2008-10 (actual) |
| NCT00498745 | Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects | Phase 1 | Completed | 2007-07 | Not listed |
| NCT01142063 | A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects | Not listed | Completed | 2010-06 | 2010-09 (actual) |
| NCT00781430 | Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease | Phase 1 | Completed | 2009-04 | 2010-02 (actual) |
| NCT00708903 | Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization) | Phase 1 | Completed | 2008-05 | 2008-07 (actual) |
Open jobs 7
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Clinical Research Associate - Remote Position | Clinical Operations | Not stated | Oct 12, 2026 | Not stated |
| Senior Oncology Sales Specialist - Austin, TX | Sales | Not stated | Oct 12, 2026 | Not stated |
| Senior Oncology Sales Specialist - Boston, MA | Sales | Not stated | Oct 12, 2026 | Not stated |
| Senior Oncology Sales Specialist - Long Island | Sales | Not stated | Oct 12, 2026 | Not stated |
| Senior Oncology Sales Specialist - Detroit, MI | Sales | Not stated | Oct 12, 2026 | Not stated |
| Senior Oncology Sales Specialist - Los Angeles, CA | Sales | Not stated | Oct 12, 2026 | Not stated |
| Strategic Account Manager - North Central Region | Sales | Not stated | Oct 12, 2026 | Not stated |
Connect
See your connections at Puma Biotechnology on LinkedIn (search by name, results not checked)